News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Blueprint Medicines To Present At Wedbush 2014 Life Sciences Management Access Conference



8/6/2014 8:48:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will present at the Wedbush 2014 Life Sciences Management Access Conference on Wednesday, August 13, 2014 at 3:05 p.m. EDT at the Le Parker Meridien Hotel in New York, NY.

About Blueprint Medicines

Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer patients. Led by a management team and advisors with world renowned expertise in cancer genomics, drug discovery, and clinical oncology, Blueprint has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint to rapidly develop potent, highly selective compounds against clear genomic driver targets. Founded in 2011, Blueprint is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit BlueprintMedicines.com.

CONTACT: Investor Relations: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Relations: David Polk Chandler Chicco Companies 310 309 1029 dpolk@chandlerchiccocompanies.com Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES